Invention Grant
- Patent Title: Methods of cancer therapy by inhibiting fusion polypeptides comprising fibroblast growth factor receptor 2 (FGFR2) and vinculin (VCL)
-
Application No.: US15301217Application Date: 2015-03-31
-
Publication No.: US10703798B2Publication Date: 2020-07-07
- Inventor: Hiroaki Tanaka , Corinne Moulon , Anne Vaslin Chessex , Jérôme Wojcik , Claudia Armenise
- Applicant: DEBIOPHARM INTERNATIONAL SA
- Applicant Address: CH Lausanne
- Assignee: DEBIOPHARM INTERNATIONAL SA
- Current Assignee: DEBIOPHARM INTERNATIONAL SA
- Current Assignee Address: CH Lausanne
- Agency: Oliff PLC
- Priority: com.zzzhc.datahub.patent.etl.us.BibliographicData$PriorityClaim@210dc737 com.zzzhc.datahub.patent.etl.us.BibliographicData$PriorityClaim@34fd5caa
- International Application: PCT/IB2015/000429 WO 20150331
- International Announcement: WO2015/150900 WO 20151008
- Main IPC: C07K14/47
- IPC: C07K14/47 ; C07K14/71 ; C07K16/18 ; C07K16/28 ; C07K16/40 ; G01N33/574 ; A61K31/4184 ; G01N33/50 ; C12N9/12 ; C12N15/113 ; C12Q1/6886
Abstract:
Fusion polypeptides have an FGFR2 polypeptide and cDNAs encode such fusion polypeptides. Methods of diagnosing the presence of the fusion polypeptides or of a gene or RNA sequence coding therefore in a sample from a subject as well as methods of treatment of a tumor instructed by the latter diagnosis.
Public/Granted literature
- US20170107271A1 FGFR FUSIONS Public/Granted day:2017-04-20
Information query
